CAR-T cell therapy has shown unparalleled success in haematological malignancies, paving the way for the field of immuno-oncology. In 2017 two therapies achieved FDA approval in the USA, and following recent approval by the EMA, it is a landmark time for the industry. Despite the huge successes there are still a number of hurdles to overcome before CAR-T can be effective in mainstream oncology beyond haematological malignancies. The European CAR-T Congress’ mission is to address the opportunities and challenges that presently face the CAR-T field, to maximise the potential of this ground-breaking therapy.Sessions include:Solid tumour targeting: overcoming the tumour microenvironmentMulti-specific & dual targeting CARsProcess development, scalability & automationAllogeneic vs Autologous: the potential of off-the-shelf therapiesPatient access, implementation & regulatory challengesAdvances in gene engineeringSafety and toxicity